Publication Name	World Journal of Methodology
Manuscript ID	23800
Country	United States

Received	2015-12-17 16:47
Peer-Review Started	2015-12-23 14:18
To Make the First Decision	2016-01-14 17:08
Return for Revision	2016-01-18 14:21
Revised	2016-01-26 00:00
Second Decision	2016-01-31 11:52
Accepted by Journal Editor-in-Chief	2016-01-31 19:31
Accepted by Executive Editor-in-Chief	2016-02-17 15:21
Articles in Press	2016-02-17 15:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-08 10:18
Publish the Manuscript Online	2016-03-18 09:50

ISSN	2222-0682 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity
Manuscript Source	Invited Manuscript
All Author List	Jun Gong, Esha Sachdev, Alain C Mita and Monica M Mita
Funding Agency and Grant Number
Corresponding Author	Monica M Mita, MD, Co-director, Division of Experimental Therapeutics Program, Samuel Oschin Compre­hensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, SCCT Mezzanine MS 35, Los Angeles, CA 90048, United States. monica.mita@cshs.org
Key Words	Reovirus; Type 3 Dearing; Oncolytic virus; Ras; Epidermal growth factor receptor; Clinical trial; Preclinical; Immune modulation
Core Tip	Reovirus has demonstrated oncolysis or preferential replication in cancer cells. The anticancer activity of reovirus has been demonstrated across a spectrum of malignancies in the preclinical setting. The relatively tolerable toxicity profile of reovirus renders it an attractive agent as part of combination therapy in cancer treatment. Reovirus-mediated immune modu-lation contributes to its antitumor activity via innate and adaptive immune responses and renders it an attractive component of immunotherapy. Here we compile the most extensive list of clinical trials investigating the anticancer efficacy of reovirus to date.
Publish Date	2016-03-18 09:50
Citation	Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol 2016; 6(1): 25-42
URL	http://www.wjgnet.com/2222-0682/full/v6/i1/25.htm
DOI	http://dx.doi.org/10.5662/wjm.v6.i1.25

Full Article (PDF)	WJM-6-25.pdf
Full Article (Word)	WJM-6-25.doc
Manuscript File	23800-Review.doc
Answering Reviewers	23800-Answering reviewers.pdf
Audio Core Tip	23800-Audio core tip.MP3
Conflict-of-Interest Disclosure Form	23800-Conflict-of-interest statement.pdf
Copyright License Agreement	23800-Copyright assignment.pdf
Peer-review Report	23800-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	23800-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	23800-Scientific misconduct check.pdf
Scientific Editor Work List	23800-Scientific editor work list.pdf